Received May 19, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 5L9A4 | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 2A3HY | — |
third extra dose administration; late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number 5L9A4, expiry date 17-JUN-2027) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) (batch number 2A3HY, expiry date 26-APR-2027) for prophylaxis. Previously administered products included Shingrix (received first dose on 28-FEB-2025 with batch number:47N3Y and expiry date:30-MAR-2027). On 17-APR-2026, the patient received the 3rd dose of Shingrix. On 22-OCT-2025, the patient received the 2nd dose of Shingrix. On 22-OCT-2025, not applicable after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: late second dose). On 17-APR-2026, the patient experienced extra dose administered (Verbatim: third extra dose administration). The outcome of the extra dose administered and drug dose administration interval too long were not applicable. Additional Information: GSK Receipt Date:13-MAY-2026 The pharmacist wanted to obtain safety information about administering a third dose of Shingrix to an immunocompetent patient.